Logo
x

Search category

Subscribe Now

Oncology Disease

Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease

Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease

  • September 14, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.